Mast cells are found in the brain, where they contribute to immune responses. They have been implicated in multiple sclerosis, but their potential role in Alzheimer's disease (AD), another inflammatory disease of the central nervous system, remains elusive. In the present study, we examined mast cell responses to amyloid P (AP) peptides 1-40 and 1-42, the major components of the Alzheimer amyloid plaques. Rat peritoneal mast cells were used as experimental model for human brain serosal mast cells. FibrillarAPI-40 andApl-42 peptides induced concentration-dependent exocytosis, as assessed by measurement of histamine secretion; exocytosis was reduced by pre-treatment with pertussis toxin and with antibodies against the CD47 receptor and the p1-integrin subunit. Fibrillar Apl-40 and Apl-42 peptides coated on heat-inactivated yeast particles and soluble fibrillar API-40 and API-42 pep tides were also recognized and phagocyted by mast cells. Uptake ofthe peptides was decreased in the presence of 4Nl, a peptide agonist of the CD47 receptor, but remained unchanged in the presence of 4NGG, a peptide derived from 4Nl which does not bind to CD47. Non-fibrillar forms ofApl-40 and 1-42 peptides were unable to elicit mast cell responses. These results show that fibrillar Ap peptides can trigger mast cells and elicit exocytosis and phagocytosis. The Ap-induced activation of mast cells operates through a CD47/Pl-integrin membrane complex coupled with Gj-protein. The present data support the hypothesis that mast cells, similarly to microglial cells, could playa major role in AD pathogenesis.
many studies have confirmed the key role of chronic inflammation in AD pathogenesis and pointed to the major involvement of microglial cells.
Microglia are the most common cells of the brain innate immune system, acting essentially as macrophages in the peripheral immune system. Microglial cells are activated in AD brain where they cluster at sites of Ap deposits. Chronic activation of microglia by fibrillar Ap peptides results in excessive release of pro-inflammatory, neurotoxic and excitotoxic mediators, especially reactive oxygen species, glutamate and TNFu, damaging the surrounding neurons and the bloodbrain barrier (3) (4) (5) . Microglial cells can actively phagocyte exogenous fibrillar Ap in vitro and in vivo (6) (7) (8) (9) . Phagocytosis occurs through the classical FeR-mediated pathways, but also through a cell surface receptor complex involving class A and/or B scavenger receptors, the U 6 Pl integrin and the CD47 receptor (7) (8) (9) . The phagocytic capacity of microglia is however impaired in AD (10) , which may act as a precipitating cause of AD. Several observations suggest that this defective clearance of Ap peptides by microglia represents a consequence of the concomitant chronic inflammation. Thus, upregulation ofpro-inflammatory genes after activation of microglial cells by Ap is associated with downregulation of several receptors and enzymes involved in Ap phagocytosis and removal, indicative of a deficit in these processes (3) . Moreover, pro-inflammatory cytokines impair microglial phagocytosis of Ap in vitro and co-incubation with anti-inflammatory agents can restore the phagocytic properties (11).
Along with microglia, mast cells contribute to immune responses in the central nervous system (CNS). Mast cells are found in most vascularized tissues and are pivotal effector cells in innate and acquired immunity (12) . They are present in the brain under physiological conditions and their number increases in inflammatory and degenerative conditions (13) (14) . Mast cells have been implicated in various inflammatory, allergic and autoimmune pathologies such as asthma, rheumatoid arthritis, psoriasis, chronic inflammatory bowel diseases, cancer and multiple sclerosis, another inflammatory disease of the CNS (15) . Several observations suggest a role also in AD. Firstly, mast cells are found in increased number in AD brains, especially close to amyloid deposits (16) . Secondly, Ap peptide is detected in the mast cells of the stomach and skin from AD patients, suggesting that it can be recognized and ingested by these cells (I 7); since mast cells express the pl-integrin subunit and the CD47 receptor (18) (19) , phagocytosis could involve a cell surface complex similar to the one already described in microglial cells. Finally, many mast cell mediators are also secreted by activated microglia and have been reported to contribute to chronic inflammation and neurotoxicity (12) .
The main objective of our study is therefore to determine whether exogenous Ap peptides can trigger mast cells. Rat peritoneal mast cells were used as an experimental model for human brain serosal mast cells. Exocytosis was assessed by measuring histamine secretion. Phagocytosis was studied quantitatively by counting ingested heatinactivated yeast particles coated with fibrillar Ap 1-40 or Ap 1-42 peptides, and qualitatively by fluorescent microscopy after labelling of ingested peptides. Involvement ofCD47 receptor, pl-integrin subunit and G j proteins in the mast cell responses triggered by Ap peptides was also analyzed.
MATERIALS AND METHODS

Materials
Ap peptides corresponding to human Ap amino acids 1-40 and 1-42 were obtained from American Peptide Co. (Sunnyvale, CA) and Bachem (Voisins-le-Bretonneaux, France). Peptides were initially dissolved in distilled water. Fibrillogenesis was induced by incubating Ap aqueous solutions at 37°C; for studying time course of fibrillogenesis, peptides were incubated for 24, 48, 72, 96, 120 and 168 h; for all other experiments, a 72 h-incubation period was used for both peptides. Monoclonal antibodies (Ab) directed against CD47 and the N-terrninal sequence of Ap peptides were purchased from Serotec (Cergy St Christophe, France); anti-CD29/P 1-integrin Ab was from Pharrningen (BD Biosciences, Le Pont-de-Claix, France). Peptide 4N 1 (RFYVVMWK) and its derivative 4NGG (GGM motif instead ofVVM motif) were from Bachem. Pertussis toxin, thioflavin T and other reagents were from Sigma (L'Isle d'Abeau Chesnes, France).
Time course ofAfJfibrils formation
Twenty IlL-aliquots of Ap solutions (5.10-5 M) were removed after 0, 24, 48, 96, 120 and 168 h of incubation at 37°C and added to 980 ul, thioflavin T 5.10-6 M in phosphate-buffered saline (PBS). Emission at 482 nm was measured immediately using a spectrofluorometer (20) . Values were corrected by emissions exhibited by 20 ).lLaliquots of distilled water processed in parallel (13.2±0.5 fluorescence units). Individual data points represent averages of duplicate samples. Additional 10 ).lL-aliquots of A~solutions were removed at the same incubation times and assayed for mast cells histamine exocytosis (see below).
Isolation ofmast cells
The method used was as in (21) . Male Wistar rats weighing 300-400 g were anesthetized, stunned and bled. Twelve mL of HEPES buffer (10 mM HEPES,137 mM NaCl, 2.7 mM KCI, 0.3 mM CaCI 2 , 1 mM MgCI 2 , 0.4 mM NaHl04, 5.6 mM glucose, 0.1% bovine serum albumin, pH 7.4) were injected into the peritoneal cavity. After a gentle abdominal massage, the peritoneal fluid was collected and centrifuged at 180g for 3 min. The pellet was resuspended in HEPES buffer and mast cells were purified on a discontinuous bovine serum albumin gradient (30 and 40%, w/v). The final pellet was resuspended in HEPES buffer (for histamine exocytosis assays) or in PBS (for phagocytosis assays) and mast cells were examined under a light microscope for viability (>95%) and purity (>97%) using Trypan blue and toluidine blue, respectively.
Histamine exocytosis assay
Methods have been described in details previously (21) . Purified mast cells (3.10 4 cells/assay) were preincubated at 37°C for 5 min, then triggered by drugs for 10 min. Reactions were terminated by adding ice-cold buffer. The amount of histamine secreted was measured fluorimetrically (22) , and expressed as a percentage of mast cell total histamine content. In each assay, values were corrected by the amount of histamine secreted in the absence of any stimulus «10%); experimental conditions were controlled by measuring in parallel the secretion triggered by 10. 2 M spermine, a classical cationic secretagogue of mast cells (48.9±6.5% of the total histamine content). Individual data points represent averages of duplicate samples.
Preparation of heat-inactivated yeast particles coated with fibrillar A~peptides
Detailed methods have been described previously (9, 23) . Briefly, yeasts (s. cerevisiae) were inactivated by heating at 120°C for 45 min. A I-mL heat-inactivated yeast suspension (2.10 8 particles) was then mixed with 20 ul. fibrillar A~(fA~) peptide aqueous solution (1 mg/mL) and incubated overnight at room temperature. Coated yeast particles were then washed three times in PBS and stored at 4°C until use.
Phagocytosis of fibrillar A~peptides coated on heatinactivated yeast particles
Purified mast cells (10 5 cells/well) were allowed to adhere on glass coverslips at 37°C in an air (95%) / CO 2 (5%)-humidified incubator. After I h, 20 ul, of the suspension of heat-inactivated yeast particles coated with fA~were added to each well (::::: 40 yeasts per mast cell) and plates were incubated for 1 h at 37°C. Mast cells were then washed three times with PBS.
In a first series of experiments, mast cells were fixed for 10 min at 4°C with 4% paraformaldehyde/PBS and permeabilized with 0.1% Triton X-I 00 for 10 min at room temperature. Non-specific binding sites were blocked with 2% BSA/PBS for 1 h at room temperature under gentle agitation. Fibrillar A~peptide coated on yeast particles was then labelled by immunofluorescence. Mast cells were observed using epifluorescence (Nikon).
In a second series of experiments, mast cells were fixed for 1 min at room temperature with 1% tannic acid solution in PBS and stained with May-Grunwald Giemsa solutions. Using this protocol, heat-inactivated yeasts that have been phagocyted appear as pink particles within mast cells, whereas extracellular heat-inactivated yeasts appear as dark violet particles (9, 24; see also Fig. 5A ). The number of phagocytic mast cells (i.e., cells displaying at least one ingested particle) and the number of phagocyted yeast particles were counted on 100 randomly selected mast cells/well at a magnification of 1000; three wells were observed for each condition. Data were expressed as the number of phagocytic mast cells and as the number of particles phagocyted per 100 mast cells. In each assay, non-coated heat-inactivated yeast particles proceeded in parallel were used as control.
Phagocytosis ofsoluble A~peptides
Purified mast cells (10 5 cells/well) were allowed to adhere on glass coverslips at 37°C in an air (95%) / CO 2 (5%)-humidified incubator for 1 h. Mast cells were then triggered with fibrillar or non-fibrillar A~1-40 or A~I-42 solutions (10-5 M). After 1 h, cells were washed three times with PBS, fixed for 10 min at 4°C with 4% paraformaldehyde/PBS and permeabilized with 0.1% Triton X-I00 for 10 min at room temperature. Nonspecific binding sites were blocked with 2% BSA/PBS for I h at room temperature under gentle agitation. Ap eptides were then labelled by immunofluorescence and analyzed using confocal laser scanning microscope (Nikon -Bio-Rad 1024 confocal imaging worskstation).
CD47 receptor immunofluorescent staining
Purified mast cells were allowed to adhere on glass coverslips for 1 h at 37°C. Cells were fixed for 10 min at 4°C with 4% paraformaldehyde/PBS. Non-specific binding sites were blocked with 2% BSAlPBS for 1 h at room temperature under gentle agitation. Primary ( l O A ug/ml.) and secondary Abs (Cy3-conjugated goat antimouse IgG; 1/2000 dilution) were incubated successively for 1 h at room temperature under gentle agitation. Coverslips were mounted and cells were observed using an epifluorescence microscope (Nikon).
Statistics
B
Data are presented as the mean±S.E.M. One way ANOVA was used to compare the differences between groups. A value for P<0.05 was considered as statistically significant.
RESULTS
477
We first studied whether non-fibrillar and fibrillar Ap 1-40 and 1-42 peptides can elicit histamine secretion by mast cells (Fig. I) . When triggered with non-fibrillar Ap 1-40 and 1-42 (0 hr-incubation), mast cells released only small amounts ofhistamine (:S 5% of total histamine content), similar to that measured in the absence of any stimulus. Fibrillogenesis was induced by incubating Ap aqueous solutions at 37°C and was followed by thioflavin T-staining. Fluorimetric emission exhibited by thioflavin Tstained Ap peptides increased with incubation time until 72 h, revealing the progressive conversion of non-fibrillar peptide to a fibrillar form. Increases were of similar magnitudes for both Ap peptides, i.e., 3-to 5-fold the values measured at 0 h. Time-course of histamine secretion elicited by 10 min-exposure of mast cells to the corresponding Ap 1-40 and 1-42 solutions (10-5 M) followed a very similar pattern, reaching a maximum value of ::::: 20% of the total histamine content at 48-72 h; these data demonstrate that activation of mast cells by Ap peptides is dependent on their fibrillar form. Both thioflavin T-f1uorimetric emission and activation of mast cells tended to decrease slowly with longer incubation times. Based on these results, the incubation time for fibrillogenesis of Ap peptides was set to 72 h for all further experiments.
Next, we showed that exocytosis from mast cells challenged with fAP occurred in a concentrationdependent manner ( Fig. 2A) . Histamine secretion reached values of 37±5% and 45±7% of the total histamine content for fAP1-40 and fAP1-42 at 10-4 M, respectively (P>0.05 comparing fAP1-40 to fAP1-42). Because of lack of solubility, greater concentrations of peptides could not be tested. Since a CD47/P I-integrin membrane complex has been implicated in the recognition of fAP peptides by microglial cells, we tested its potential involvement in the fAp-stimulated mast cells exocytosis. The expression of the CD47 at the cell surface was verified by immunofluorescent staining (Fig. 3) . Pre-treatment of mast cells with anti-CD47 and anti-p1-integrin antibodies resulted in a 60 to 70% inhibition of histamine secretion (Fig. 2B ). The amount of histamine secreted was reduced similarly by pertussis toxin (Fig. 2B ). Altogether, these data suggested that fAP peptides could trigger mast cell exocytotic responses through a CD47/P 1 -integrinl pertussis toxin-sensitive G-protein pathway.
Activated mast cells not only release numerous mediators, but also display phagocytic properties. Therefore, we aimed at evaluating whether mast cells can phagocyte Ap peptides. Phagocytic responses of mast cells were first investigated using fAp-coated heat-inactivated yeasts particles as model for the Ap deposits of AD plaques. Once challenged with fAp-coated yeast particles, many mast cells appeared with bright fluorescent labelling for Ap peptides, indicating interactions between the cells and fAp-coated yeast particles (Fig. 4 ).
IfAJi1-40 I
IfAJi1· 42 I Fig. 4 . Stimulation of rat peritoneal mast cells phago cytosis by fibrillar A~1-40 and A~1-42 coated on heat-inactivatedyeast particles. Rat p eritoneal mast cells were allowed to adhere on glass coverslips for 1 h at 3JOC, then triggeredfor 1 h withfibrillar A~(fA~) coated on heat-inactivated yeast particles. Coated fA~l-40 and fA~1-42 were labelled by immunofluorescence after perm eabilization ofmast cells. Mast cells were examined by phase contrast (a, c) and epifluorescence microscopy (b, 
d). Arrows exemplify mast cells displaying spec ific fluor escent labelling ofA~peptides; arrow heads point to mast cells on which no specificfluorescent labelling ofAp ep tides is detected.
Phagocytic responses were quantified after May-Grunwald Giemsa staining of mast cells (Fig. 5A ). Exposure to fAf)I-40-coated yeast particles triggered phagocytosis in 53% ofthe mast cell population (Fig.  5B) ; the percentage of responding cells was slightly higher when challenged with fAf)I-42 (61%). The number of ingested particles was of similar magnitude (150-180 particles per 100 mast cells) whether stimulated by fAf)I-40 and fAf)I-42 (Fig.  5C ). In the presence of the CD47 receptor ligand, 4N I (10-4 M), fAf)-stimulated mast cell phagocytic responses were largely reduced ( Fig. 5D and 5E) . In contrast, the same concentration of 4NGG , a peptide derived from 4NI but which does not bind to CD47 , did not affect mast cell phagocytosis ( Fig.  5D and 5E ). Neither 4N I nor 4NGG influenced mast cell phagocytosis of non-coated yeast particles (not shown). In order to establish directly that mast cells phagocyte fAf) peptides, cells were exposed to fibrillar or non-fibrillar Af) solutions (10-5 M) before immunofluorescent labelling of the peptide. Mast cells displayed no Af) fluorescence when triggered with non-fibrillar peptides. In contrast, strong fluorescent labelling for Af) was associated with mast cells challenged with fAf)I-40 or fAf)I-42 (not shown) . Confocal Z-scanning through mast cells showed the intracellular localization of fluorescent labelling, confirming the ingestion of the fibrillar peptides.
DISCUSSION
Mast cells have been implicated in several chronic inflammatory pathologies (e.g., multiple sclerosis , rheumatoid arthritis , Crohn's disease , asthma, cancer .. .) (15) . Previous observations supported the hypothesis of an implication of mast cells also in AD (see Introduction), but direct evidence for a stimulatory action of Af) peptides on these cells was lacking . The present results show for the first time that fibrillar Af) peptides 1-40 and 1-42, the major components of the Alzheimer amyloid plaques, are recognized by rat peritoneal mast cells and can trigger exocytotic and phagocytic responses . Since rat peritoneal mast cells are considered as an experimental model for the human serosal brain mast cells, these findings suggest that mast cells could playa key role in chronic local inflammation and amyloid plaque formation, thus contributing to AD pathogenesis. Our data also point to great similarities between the Af)-induced activation of mast cells and activation of microglial cells, the classical brain phagocytes.
Exposure of rat peritoneal mast cells to fibrillar Af) peptides induced the release of histamine, one of the preformed granule-associated mediators. This indicates mast cell degranulation, and hence, secretion of the other granule components, including proteases (tryptase, chymase) , TNFa and vascular endothelial growth factor (VEGF) (12) . Most of these granule-associated mediators can favor the development of AD lesions. Histamine, VEGF and TNFa increase blood-brain barrier permeability (25) (26) , thus promoting local inflammation; blood-brain barrier disruption is a well established early event in multiple sclerosis and has also been observed in AD (27) . Histamine can also induce neuronal death (28) and accumulation of histamine released by mast cells has been involved in ischemic neurodegeneration (29) . Finally, catalytic activity of mast cell granule proteases can generate amyloidogenic peptides from the amyloid precursor protein and the serum amyloid A (SAA), thus contributing to amyloid plaque formation (30) . Activated mast cells also synthetize de novo and release a wide variety of lipid mediators, cytokines and chemokines, and superoxide radicals (12) . Many of them are also secreted by Ab-stimulated microglia and have been reported to contribute to AD pathogenesis through pro-inflammatory and neurotoxic effects. Rat peritoneal mast cells exposed to fibrillar Ap peptides also displayed phagocytic responses. Phagocytosis was shown using heat-inactivated yeast particles coated with fibrillar Ap peptides. This experimental model was developed in our laboratory as an attempt to reproduce in vitro the Ap deposits of AD plaques and has proved reliable for studying the membrane receptors implicated in fAP phagocytosis by microglial cells (9, 23) . Exposure of mast cells to fAp-coated yeast particles triggered phagocytosis in about 30% of the cell population. Of note, fAP immobilized on microspheres elicited microglia phagocytic responses of the same range (8), suggesting similar sensibilities of the two cell types. Binding and internalization of fAP were also observed directly after fluorescent labelling of the peptides and confocal Z-scanning through the cells. Phagocytosis was not quantified in these latter experiments, but the same peptide concentration (10-5 M, i.e., 45 ug/ml.) was reported to trigger phagocytosis by microglial cells (8) . Altogether, our data support the hypothesis that mast cells could contribute to the clearance of AP, similarly to microglial cells.
at 37°C). Mast cells were stained with May-Grunwald Giemsa. (A) Panel a shows phagocytic (arrows) and non-phagocytic (arrow head) mast cells; with higher magnification (panel b), ingested yeasts appear as pink particles within mast cells (arrow) whereas extracellular yeas ts appear as dark violet particles (arrow head); panels c, d and e show examples ofmast cells triggered with non-coated yeasts particles (control) and with fA~
Mast cell responses to Ap were dependent on the fibrillar form of the peptides. Thus, histamine secretion and phagocytosis were noticed only when mast cells were exposed to fibrillar peptides. In our study, conversion ofnon-fibrillar peptide to a fibrillar form was appreciated bythioflavin Tstaining. Binding of thioflavin T to fibrils of Ap peptides modifies the fluorescence absorption and emission spectra of the dye, giving rise to enhanced emission at 482 nm (20) . The fluorescence intensity correlates with the amount offibrillar aggregates observed with electron microscopy (31) , and therefore represents a reliable marker of fibrillogenesis over time. Once again, the differential sensitivity of mast cells to the states of peptide assembly reminds of previously reported microglia reactivity. Hence, non-fibrillar peptide was repeatedly found ineffective in activating microglial cells (3, (5) (6) (8) (9) . In line with these observations, neurotoxic effects were attributed only to the fibrillar form of amyloid peptides (32) (33) . Among the various forms of fibrillar amyloid peptides, Ap 1-42 is usually considered as the most pathological (1) . Thus, the majority of the Ap produced in the normal brain is of the shorter form (i.e., and an increase in Ap 1-42 levels has been identified as an early event in AD pathogenesis. Accumulation of Ap 1-42 would initiate the amyloid plaque formation and seed the further deposition of the other forms of Ap peptides. However, experimental data do not highlight obvious differences in toxicity, since the most common forms of Ap (25-35, 1-40 and 1-42) stimulate microglial cells and induce neuronal death with similar potencies (7, 9, 32) . In agreement with these observations, mast cells displayed similar sensitivities towards fAP1-40 and fAP1-42 in this study.
A cell surface receptor complex comprising the CD47 and pj-integrins was involved in the binding of fAP peptides to microglial cells, and the subsequent secretory and phagocytic responses (7) (8) .
The present data suggest that activation of mast cells by fAP peptides operates -at least partly -through a similar CD47/P t-integrin membrane complex coupled with Gj-protein. Hence, fAp-induced exocytosis was largely reduced after blockade of the CD47 receptor and the pj-integrin subunit, as well as after pre-treatment with pertussis toxin. Pertussis toxin prevents receptor I G-protein interaction by ADP-ribosylation of a cysteine residue on a subunits of G., G , G, and G . However, the only J 0 gust G-proteins involved in mast cell activation were identified as G i2 and G j3 (34) , strongly supporting the conclusion that the pertussis toxin-sensitive Gprotein evidenced in the present study belongs to the G. family. Phagocytosis of fAP was halved in the presence of 4NI, a synthetic peptide derived from thrombospondin which bears the VVM amino acid sequence necessary for binding to CD47 (35) , suggesting a competition between the two ligands for a common binding site at the mast cell surface.
In contrast, phagocytosis of fAP was unaffected by 4NGG, a variant form of 4NI which does not bind to CD47 (the CD47-binding motif VVM present in the amino acid sequence of 4N 1 was replaced by an inactive GGM motif in 4NGG (35)). This latter observation further supports the idea that fAã nd 4Nl interact with mast cells through the same membrane receptor, i.e., CD47. The CD47 receptor can associate with integrins of the~1'~2 and~3 families. Sensitivity of the CD4 7/integrin-mediated effects to pertussis toxin was repeatedly observed, leading to the proposal that the association of the a~-integrin transmembrane segments (TMS) to the five TMS of CD47 would mimic a classical 7TMS receptor and allow the functional coupling with Gproteins (36) . CD47-,~l-integrinand/or Gj-proteindependent reactivity of mast cells has been reported (18) (19) . Also in agreement with the present data, McDonald et al. (37) described a recombinant form of the CD47-binding domain of thrombospondin which triggers Gj-protein-dependent signalling; of interest, the high potency of this recombinant CD47 ligand was attributed to its~-sheet amyloidlike conformation. Finally, Gj-proteins were also implicated in the SAA-induced mast cell chemotaxis (38) . However, the a-integrin subunit and intracellular signalling may differ between mast cells and microglia. Thus, a6~I integrin identified on microglial cells (7-8) is not expressed on mast cells (39) ; further investigations are needed to identify the o-integrin subunit in mast cells, as well as other possibly implicated~-integrin subunits. Similarly, our results reveal a coupling to Gi-protein in mast cells, but implication of G-proteins in A~-induced microglial cell responses remains controversial (7, 40) . In summary, our data show that mast cells and microglial cells display comparable responsiveness to amyloid peptides. Hence, fibrillar A~peptides interact -at least partly-through a CD47/~1-integrin complex at the membrane surface of both cell types to trigger exocytosis and phagocytosis. The present results support the hypothesis that mast cells could play a role in AD pathogenesis. However, the beneficial or deleterious outcome of mast cells activation in AD, as in other chronic inflammatory diseases, remains to be characterized.
